|
|
Article: Xencor Receives Advanced Technology Program Grant for Safer Protein Therapeutics; Grant to Support the Rational Design of Non-immunogenic Proteins.
- Article from:
- Business Wire
- Article date:
- October 9, 2002
CopyrightCOPYRIGHT 2002 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Business Editors & Health/Medical Writers
MONROVIA, Calif.--(BUSINESS WIRE)--Oct. 9, 2002
Xencor today announced that it has been awarded a $2 million Advanced Technology Program grant from the National Institute of Standards and Technology to support the discovery of safer and more effective protein therapeutics. The three-year federal grant, titled "Rational Design of Non-immunogenic Proteins," supports the development of Xencor's ImmunoPDA(TM) technology to create new, non-immunogenic proteins optimized for therapeutic use and to eliminate immunogenicity from known protein drugs.
The promise of biotherapeutics is threatened by the potential ...